Early efficacy results in the Alumites study: A randomized, controlled, multicenter, phase IV study with house dust mites subcutaneous immunotherapy. Two months symptoms and medication scores
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Fecha de publicación
2015Título de revista
Allergy
Tipo de contenido
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)